Magna International is undervalued with a trailing P/E of 7.01x and EV/EBITDA of 4.55x, presenting a 23% margin of safety. Learn more on MGA stock here.
Natco Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Agrochemicals, Export Incentives, Other Operating Revenue, Scrap for the year ending 31-Mar-2024.For the quarter ended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback